HeartBeam, Inc. (BEAT) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. HeartBeam, Inc. is a cardiac technology company developing higher-resolution ambulatory Electrocardiogram (ECG) solutions. The company operates as a single segment based in Santa Clara, California. As of September 30, 2025, the company had 16 employees and 34,340,727 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(5.26) million | $(15.71) million | $(14.54) million |
| Operating Expenses | $5.29 million | $15.83 million | $14.94 million |
| Cash and Equivalents | $1.86 million (Sep 30, 2025) | $1.86 million (Sep 30, 2025) | $2.38 million (Dec 31, 2024) |
| Net Cash Used in Operations | N/A | $(11.08) million | $(10.32) million |
| Net Cash Provided by Financing | N/A | $10.75 million | $0.11 million |
| Total Liabilities | $2.47 million | $2.47 million | $1.62 million (Dec 31, 2024) |
Note: The filing does not provide specific margin percentages as there is no revenue. The company expects no material commercial revenue in 2025.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss for the nine months ended September 30, 2025, increased by $1.17 million (8%) compared to the same period in 2024, primarily due to higher R&D expenses.
- R&D Expenses: Increased by $1.93 million (24%) year-over-year for the nine-month period. This was driven by a $1.1 million increase in product development, a $1.2 million net increase in headcount costs, and $1.2 million in additional stock-based compensation.
- G&A Expenses: Decreased by $1.05 million (15%) year-over-year for the nine-month period, attributed to cost reduction efforts, lower consultant costs, and a change in estimate for milestone option recognition.
- Capital Raise: In February 2025, the company completed a public offering raising approximately $11.5 million in gross proceeds ($10.3 million net), significantly boosting financing cash flows compared to the prior year.
- Liquidity: Cash and cash equivalents decreased from $2.38 million at year-end 2024 to $1.86 million at September 30, 2025, despite the capital raise, due to operating burn.
Guidance, Outlook, and Risks
- Going Concern: Management has raised substantial doubt regarding the company's ability to continue as a going concern. With approximately $1.9 million in cash, existing liquidity is insufficient to fund operations for the next twelve months. Continued operations depend on raising additional capital.
- Regulatory Milestones: The HeartBeam System received FDA clearance on December 13, 2024. A 510(k) submission for software algorithms to synthesize a 12-Lead ECG was filed in January 2025. Management expects clearance by December 31, 2025.
- Commercialization: The company is running an "Early Access Program" to gather feedback but does not anticipate revenue from it. Commercial launch is anticipated following FDA clearance of the 12L synthesis software.
- Strategic Partnerships: Announced a collaboration with AccurKardia to integrate automated ECG interpretation, aiming to reduce development costs and timelines.
- Financing Capacity: The company has an At-the-Market (ATM) agreement with $15.5 million remaining available for issuance as of the filing date.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.86 million cash balance against the stated burn rate and the timeline for the next capital raise.
- FDA Clearance Status: Monitor the status of the 510(k) submission for the 12-Lead ECG synthesis software, with a target clearance date of December 31, 2025.
- Dilution Risk: Assess the impact of the ATM program and potential future equity financings on shareholder dilution.
- Revenue Timeline: Confirm the commercial launch date and initial revenue projections post-FDA clearance, as no revenue is expected in 2025.
- Stock-Based Compensation: Review the $3.72 million in stock-based compensation expense for the nine months ended September 30, 2025, and the remaining unrecognized cost of approximately $7.5 million.